Biotech Deal-Making as Industry Barometer
This article was originally published in Start Up
Given the overriding interest among investors in liquidity, corporate dealmaking in biotech now only very rarely serves as validation for IPOs, let alone boosting stock prices. Instead, there's been a much sharper focus on the strategic value of dealmaking. It has become the means by which a company can protect the long-term value of an asset or asset base for maximum flexibility in the future.
You may also be interested in...
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.
Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.